Computer-assisted design of novel 1,4-dihydropyridine calcium channel blockers

References

• World Health Organization. [cited 2013 Jul 20]. Available from: http://www.who.int.
   Google Scholar
• NelsonM. Drug treatment of elevated blood pressure. Aust Prescr. 2010;33:108–112.
   Web of Science ®Google Scholar
• WolowykMW, KnaussEE, AbrahamS, AmitalG. Calcium channel modulators in heart and smooth muscle: basic mechanisms and pharmacological aspects. Weinheim: VCH; 1990.
   Google Scholar
• FossheimJ. Crystal structure of the dihydropyridine calcium antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data. J Med Chem. 1986;29:305–307.
   PubMed Web of Science ®Google Scholar
• ScholzGH, ViewegS, UhligM, ThormannM, KlossekP, GoldmannS, HofmannHJ. Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class. J Med Chem. 1997;40:1530–1538.
   PubMed Web of Science ®Google Scholar
• KassRS, ArenaJP, ChinS. Block of L-type calcium channels by charged dihydropyridines. J Gen Physiol. 1991;68:63–75.
   Web of Science ®Google Scholar
• KassRS, ArenaJP. Influence of pH on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J Gen Physiol. 1989;93:1109–1127.
   PubMed Web of Science ®Google Scholar
• KwanYW, BangaloreR, LakitshM, GlossmannH, KassRS. Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site. J Mol Cell Cardiol. 1995;27:253–262.
   PubMed Web of Science ®Google Scholar
• MiriR, McEwenCA, KnausEE. Synthesis and calcium channel modulating effects of modified Hantzsch nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(pyridinyl or 2-trifluoromethylphenyl)-5-pyridinecarboxylates. Drug Dev Res. 2000;51:225–232.
   Web of Science ®Google Scholar
• MiriR, HowlettSE, KnausEE. Synthesis and calcium channel modulating effects of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(thienyl)-5-pyridinecarboxylates. Arch Pharm. 1997;330:290–294.
   PubMed Web of Science ®Google Scholar
• ShafieeA, MiriR, DehpourAR, SolimaniF. Synthesis and calcium channel antagonist activity of nifedipine analogues containing nitroimidazolyl substituent in guinea-pig ileal smooth muscle. Pharmaceut Sci. 1996;2:541–543.
   Google Scholar
• MiriR, NiknahadH, VesalGH, ShafieeA. Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5-pyridinedicarboxylates. Il Farmaco. 2002;57:123–128.
   PubMedGoogle Scholar
• SarseroD, FujiwaraT, MolenaarP, AngusJA. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists. Br J Pharmacol. 1998;145:109–119.
   Web of Science ®Google Scholar
• SafarpourMA, HemmateenejadB, MiriR, JamaliM. Quantum chemical QSAR study of some newly synthesized calcium channel blockers. QSAR Comb Sci. 2003;22:997–1005.
   Google Scholar
• FreitasMP, BrownSD, MartinsJA. MIA-QSAR: a simple 2D image-based approach for quantitative structure–activity relationship analysis. J Mol Struct. 2005;738:149–154.
   Web of Science ®Google Scholar
• ACD/ChemSketch. Version 10.02. Toronto, ON: Advanced Chemistry Development, Inc.; 2006.
   Google Scholar
• Matlab 7.5.Natick, MA: Mathworks, Inc.; 2007.
   Google Scholar
• FreitasMP. Multivariate QSAR: from classical descriptors to new perspectives. Curr Comp-Aid Drug Des. 2007;3:235–239.
   Web of Science ®Google Scholar
• CormanichRA, FreitasMP, RittnerR. 2D Chemical drawings correlate to bioactivities: MIA-QSAR modelling of antimalarial activities of 2,5-diaminobenzophenone derivatives. J Braz Chem Soc. 2011;22:637–642.
   Google Scholar
• Pirouette 3.0.1. Gainessville, FL: Infometrix, Inc.; 2006.
   Google Scholar
• MitraI, SahaA, RoyK. Exploring quantitative structure–activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Mol Simul. 2010;36:1067–1079.
   Web of Science ®Google Scholar
• RoyK, MitraI, KarS, OjhaPK, DasRN, KabirH. Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model. 2012;52:396–408.
   PubMed Web of Science ®Google Scholar
• RoyPP, PaulS, MitraI, RoyK. On two novel parameters for validation of predictive QSAR models. Molecules. 2009;14:1660–1701.
   PubMed Web of Science ®Google Scholar
• OjhaPK, MitraI, DasRN, RoyK. Further exploring rm2 metrics for validation of QSPR models. Chemom Intell Lab Syst. 2011;107:194–205.
   Web of Science ®Google Scholar
• NunesCA, FreitasMP, PinheiroACM, BastosSC. Chemoface: a novel free user-friendly interface for chemometrics. J Braz Chem Soc. 2012;23:2003–2010.
   Web of Science ®Google Scholar
• HuberI, WapplE, HerzogA, MitterdorferJ, GlossmannH, LangerT, StriessnigJ. Conserved Ca2+ antagonist binding properties and putative folding structure of a recombinant high affinity dihydropyridine binding domain. Biochem J. 2000;347:829–836.
   PubMed Web of Science ®Google Scholar
• BarreiroG, GuimarãesCRW, de AlencastroRB. A molecular dynamics study of an L-type calcium channel model. Protein Eng. 2002;5:109–122.
   Google Scholar
• ZhorovBS, FolkmanEV, AnanthanarayananVS. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists. Arch Biochem Biophys. 2001;393:22–41.
   PubMed Web of Science ®Google Scholar
• ThomsenR, ChristensenMH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49:3315–3321.
   PubMed Web of Science ®Google Scholar
• PearsonK. On lines and planes of closest fit to systems of points in space. Philos Mag. 1901;6:559–572.
   Google Scholar
• GolbraikhA, TropshaA. Beware of q2!. J Mol Graph Model. 2002;20:269–276.
   PubMed Web of Science ®Google Scholar
• GeçenN, SaripinarE, YanmazE, ŞahinK. Application of electron conformational–genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction. J Mol Model. 2012;18:65–82.
   PubMed Web of Science ®Google Scholar
• MohajeriA, HemmateenejadB, MehdipourA, MiriR. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GAPLS. J Mol Graph Model. 2008;26:1057–1065.
   PubMed Web of Science ®Google Scholar
• KahramanP, TurkayM. Classification of 1,4-dihydropyridine calcium channel antagonists using the hyperbox approach. Ind Eng Chem Res. 2007;46:4921–4929.
   Web of Science ®Google Scholar
• YaoX, LiuH, ZhangR, LiuM, HuZ, PanayeA, DoucetJP, FanB. QSAR and classification study of 1,4-dihydropyridine calcium channel antagonists based on least squares support vector machines. Mol Pharm. 2005;2:348–356.
   PubMed Web of Science ®Google Scholar
• TakahataY, CostaMCA, GaudioAC. Comparison between neural networks (NN) and principal component analysis (PCA): structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues). J Chem Inf Comput Sci. 2003;43:540–544.
   PubMedGoogle Scholar
• SchleifezrKJ, TotE. CoMFA, CoMSIA and GRID/GOLPE studies on calcium entry blocking 1,4-dihydropryridines. Quant Struct Act Relat. 2002;21:239–248.
   Google Scholar
• PinheiroJR, BitencourtM, da CunhaEFF, RamalhoTC, FreitasMP. Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches. Bioorg Med Chem. 2008;16:1683–1690.
   PubMed Web of Science ®Google Scholar
• AntunesJE, FreitasMP, da CunhaEFF, RamalhoTC, RittnerR. In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil. Bioorg Med Chem. 2008;16:7599–7606.
   PubMed Web of Science ®Google Scholar
• MiriR, JavidniaK, Kebriaie-ZadehA, NkhnahadH, ShayganiN, SemnanianS, ShafieeA. Synthesis and evaluation of pharmacological activities of 3,5-dialkyl 1,4-dihydro-2,6-dimethyl-4-nitroimidazole-3,5-pyridine dicarboxylates. Arch Pharm. 2003;336:422–428.
   PubMed Web of Science ®Google Scholar
• LipinskiCA, LombardoF, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3–25.
   Web of Science ®Google Scholar
• ModaTL, TorresLG, CarraraAE, AndricopuloAD. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics. 2008;24:2270–2271.
   PubMed Web of Science ®Google Scholar